Lisa Palacios

Healthcare Program Manager

[UT MD Anderson @UTMDAnderson]

Early results show encouraging efficacy of a novel triplet combo of cladribine, venetoclax, and alternating azacitidine and low-dose cytarabine in patients with higher-risk MDS and CMML, presented by our Dr. @GMontalbanBravo at #ASCO25. Read more: https://t.co/61jyQFGiFu @ASCO #EndCancer

[UT MD Anderson @UTMDAnderson]

New data from the CADENZA study shows pivekimab sunirine (PVEK) led to a 70% CR + CRc rate in frontline BPDCN with a manageable safety profile. Presented by Dr. Naveen Pemmarju at #ASCO25. #EndCancer https://t.co/mu9oBJbu2P
@doctorpemm

[UT MD Anderson @UTMDAnderson]

Our Dr. Naval @Daver_Leukemia shared an encouraging safety profile for the first-in-class macrophage checkpoint inhibitor, bexmarilimab, in combination with azacitidine for treatment of higher-risk myelodysplastic syndrome in both the frontline and refractory/relapsed settings. @ASCO #ASCO25 #EndCancer

[UT MD Anderson @UTMDAnderson]

Updated results from the Phase III COMMANDS trial, presented by our Dr. Guillermo Garcia-Manero at #ASCO25, support luspatercept as the standard of care for anemia in patients with lower-risk myelodysplastic syndromes. @garciamanero @ASCO #EndCancer

[UT MD Anderson @UTMDAnderson]

In a study of combined Pirtobrutinib, Venetoclax and Obinutuzumab as a first-line treatment for patients with chronic lymphocytic leukemia (CLL) with a median follow up of nearly a year, no patients have progressed or died, our @NitinJainMD reported. Read more: https://t.co/AJAmBxX6RH #ASH24 #EndCancer

[Nitin Jain @NitinJainMD]

Mini MDACC reunion at the poster session yesterday #ASH24
@TapKadia @FadiHaddad_MD @HannahGoulart @JenMarvinPeek @CRausch_PharmD @NadyaJammal Alex Lovell Alex Bazinet

[Society of Hematologic Oncology (SOHO) @SocietyofHemOnc]

Watch the full discussion between @DrHKantarjian and @NitinJainMD on #CLL, BTK inhibitors, and more during #SOHO2024 on YouTube at https://t.co/64ekDwarIU

[Society of Hematologic Oncology (SOHO) @SocietyofHemOnc]

Watch this video with @charliecraddock and @DrHKantarjian on #AML progress, from the intro of intensive chemotherapy to targeted therapies to transplant. #MedTwitter
https://t.co/1h0I5Ok5jM

[Shivani Modi MD @smodimd]

Amazing talk about #leukemia with the GOAT @NitinJainMD @SocietyofHemOnc #SOHO2024 @MDAndersonNews looking forward to collaborating with upcoming research and working with you!

[PeerView @PeerView]

Watch Naval Daver, MD & Tapan Kadia, MD discuss the latest Acute Myeloid Leukemia #AML updates from #SOHO2024 - to participate, visit: https://t.co/cBebiHCBj9 https://t.co/Hkxm2wxPsW

[Lymphoma Hub @lymphomahub]

CONGRESS | #SOHO2024
William Wierda, @MDAndersonNews, presents post hoc exploratory analysis results of the phase I/II TRANSCEND CLL 004 study evaluating characteristics associated with response to liso-cel in pts with R/R CLL/SLL (n=87). OR and CR rates did not correlate with age and high-risk features at screening including unmutated IGHV, TP53m, 1del(7p), or complex karyotype. Patients receiving ≤3 prior treatments had numerically higher OR rate (54.5%) than those receiving >3 prior treatments (44.6%).
@wwierda #lymsm #MedicalCongress

[Lymphoma Hub @lymphomahub]

CONGRESS | #SOHO2024
William Wierda, @MDAndersonNews, discusses whether continuous therapy is the best option for high-risk pts with CLL. In pts with del(17p)/TP53 mutations, second generation covalent BTK inhibitors (such as ibrutinib) show median PFS of 6+ years, however, are associated with continuous risk of AEs or toxicities. Other options include non-covalent BTK inhibitors & BCL2 inhibitors.
@wwierda #lymsm #MedicalCongress

[ALL Hub @ALL_Hub_]

CONGRESS | #SOHO2024 |
Elias Jabbour, @MDAndersonNews shares data of D-D Mini-HCVD-inotuzumab-blinatumomab for the treatment of R/R ALL; concluding with the feasibility of the combination based on safety and efficacy data. Overall 1-year OS 90% vs 66%.
#ALLsm #leusm

[Nitin Jain @NitinJainMD]

Dr John Seymour giving Dr Michael Keating plenary award lecture at #SOHO24 @SocietyofHemOnc

First patient ever treated with venetoclax (previously called ABT-199) was in June 2011 in Australia with Dr Seymour.

Amazing how this drug has changed the practice of leukemia care, especially CLL and AML 👏👏 @DrHKantarjian @garciamanero

[Nitin Jain @NitinJainMD]

With the @MDAndersonNews CLL research team at #SOHO24 @SocietyofHemOnc
An amazing group dedicated to the care of patients with CLL 👏👏

[OncLive.com @OncLive]

Dr Wierda discussing best option for high risk CLL pts - I like this slide as a visual for hypothetical length of time on/off therapy based upon therapeutic sequencing @calliecoombsmd #SOHO24

[Mike Thompson, MD, PhD, FASCO @mtmdphd]

Listening to some of my favorite Texans tonight at #SOHO24 #SOHO2024 #CARTcell #mmsm #lymsm #AMLsm #leusm @Lymphoma_Doc @ldandersonjr
@Daver_Leukemia @TapKadia

[Mike Thompson, MD, PhD, FASCO @mtmdphd]

Venetoclax in AML - @Daver_Leukemia @TapKadia
#SOHO24 #SOHO2024 #AMLsm #leusm #PrecisionMedicine

[Mike Thompson, MD, PhD, FASCO @mtmdphd]

KMT2Ar AML - @Daver_Leukemia @TapKadia
#SOHO24 #SOHO2024 #AMLsm #leusm #PrecisionMedicine Menin inhibitors #caxtx

[Naveen Pemmaraju, MD @doctorpemm]

👉👉👉Wonderful to attend #SOHO24 #SOHO2024 !! Amazing to see its rapid growth ! Dr @FadiHaddad_MD Prof @doctorpemm Prof @GCC_Cortes || @SocietyofHemOnc #leusm #endcancer